sábado, 14 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 11, 2026

Aduro Clean Technologies gibt Ausgabepreis für ein garantiertes öffentliches Emissionsangebot in Höhe von 15,64 Millionen US-Dollar sowie eine gleichzeitige Privatplatzierung von bis zu 7,17 Millionen US-Dollar bekannt

View original at globenewswire.com
Aduro Clean Technologies gibt Ausgabepreis für ein garantiertes öffentliches Emissionsangebot in Höhe von 15,64 Millionen US-Dollar sowie eine gleichzeitige Privatplatzierung von bis zu 7,17 Millionen US-Dollar bekannt LONDON, Ontario, June 11, 2026 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The company intends to rely on the exemption under Section 602.1 of the TSX Company Manual, which provides that the TSX does not apply its standards to certain transactions involving eligible issuers listed on a recognized exchange.

    60% confidence
  • Aduro's Hydrochemolytic™ technology uses water as the primary active ingredient in a chemical platform that operates at relatively low temperatures and costs.

    60% confidence
  • The company anticipates that certain insiders may participate in the LIFE offering, constituting a 'related party transaction' under MI 61-101, but expects to rely on exemptions from formal valuation and minority shareholder approval requirements as insider participation is not expected to exceed 25% of the company's market capitalization.

    60% confidence
  • The public offering is expected to close on or about June 11, 2026, subject to satisfaction of customary closing conditions, including listing of offered shares on the TSX and Nasdaq and receipt of all required TSX and Nasdaq approvals.

    60% confidence
  • The LIFE offering is expected to close on or about the closing date or another date determined by the company, but no later than 45 days after the date of this press release. The LIFE offering may close in one or more tranches.

    60% confidence
  • The public offering is not conditional on completion of the LIFE offering, and the LIFE offering is not conditional on completion of the public offering.

    60% confidence
  • Aduro intends to use net proceeds from the offering for planning, development, and construction of the world's first industrial-scale FOAK demonstration facility, ongoing R&D expenses, and remaining amounts for general corporate purposes and working capital.

    60% confidence

Data points we hold from this source

Aduro Clean Technologies Inc. · gross proceeds life offering7169810 USD
Aduro Clean Technologies Inc. · gross proceeds public offering15635404 USD
Aduro Clean Technologies Inc. · shares offered public1028645 shares
Aduro Clean Technologies Inc. · shares offered life private placement471698 shares
Aduro Clean Technologies Inc. · offer price usd15.20 USD_per_share
Aduro Clean Technologies Inc. · offer price cad21.20 CAD_per_share
Aduro Clean Technologies Inc. · gross proceeds total combined22805214 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,577 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Aduro Clean Technologies gibt Ausgabepreis für ein garantiertes öffentliches Emissionsangebot in Höhe von 15,64 Millionen US-Dollar sowie eine gleichzeitige Privatplatzierung von bis zu 7,17 Millionen US-Dollar bekannt — Source | Via News | pt.VIA.NEWS